Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $202.9 million.

  • Enanta Pharmaceuticals' Total Liabilities fell 1432.02% to $202.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $202.9 million, marking a year-over-year decrease of 1432.02%. This contributed to the annual value of $216.0 million for FY2025, which is 1284.02% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Total Liabilities stood at $202.9 million for Q4 2025, which was down 1432.02% from $216.0 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Total Liabilities registered a high of $257.3 million during Q2 2023, and its lowest value of $31.7 million during Q1 2021.
  • For the 5-year period, Enanta Pharmaceuticals' Total Liabilities averaged around $150.2 million, with its median value being $209.5 million (2025).
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 1692.4% in 2022, then surged by 44533.7% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Total Liabilities (Quarter) stood at $56.2 million in 2021, then decreased by 16.92% to $46.7 million in 2022, then skyrocketed by 406.7% to $236.6 million in 2023, then rose by 0.09% to $236.8 million in 2024, then decreased by 14.32% to $202.9 million in 2025.
  • Its Total Liabilities stands at $202.9 million for Q4 2025, versus $216.0 million for Q3 2025 and $221.8 million for Q2 2025.